Preoperative oral Pentoxifylline in case of CABG with severe LV dysfunction (EF=30%) and their complications

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201107197060N1

Enrollment

178

Registered

2013-05-19

Start date

2011-09-08

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease. Chronic ischaemic heart disease

Interventions

Intervention 1: In control group: only routine drugs. Intervention 2: In intervention group: Pentoxifilline 400 mg oral tablet, TDS, 3 days beside the routine drugs.

Treatment - Drugs

In control group: only routine drugs.

In intervention group: Pentoxifilline 400 mg oral tablet, TDS, 3 days beside the routine drugs.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria were isolated CABG using cardiopulmonary bypass pump (CPB) adult candidates with low ejection fraction (EF = 30%). Exclusion criteria: previous renal failure (RF); recent myocardial infarction (MI) (less than 4 weeks ago); uncontrolled diabetes and use of anti-inflammatory drugs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ejection Fraction. Timepoint: pre and early post-operation. Method of measurement: echocardiography.	—

Secondary

Measure	Time frame
Mortality. Timepoint: Early Post-Operation. Method of measurement: Clinical.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoheil Mansourian

Tehran Heart Center

soheilmansourian@yahoo.com+98 21 8802 9600

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026